Literature DB >> 16076030

Generation of anti-Neu-glycolyl-ganglioside antibodies by immunization with an anti-idiotype monoclonal antibody: A self versus non-self-matter.

Ana María Hernández1, Mabel Rodríguez, Alejandro López-Requena, Irene Beausoleil, Rolando Pérez, Ana Maria Vázquez.   

Abstract

We have previously generated a murine anti-idiotype (Ab2) monoclonal antibody (mAb) to a murine Ab1 mAb, named P3, which selectively binds Neu-glycolyl (NeuGc)-sialic acid on several monosialo- and disialogangliosides, and also reacts with sulfatides and antigens expressed in human melanoma and breast tumors. This Ab2 mAb, designated as 1E10, induced anti-anti-idiotype antibodies (Ab3) in mice and cancer patients. These Ab3 generated by 1E10 mAb were characterized by bearing P3 mAb idiotopes (Ab3, Id +). But when the specificity of these Ab3 antibodies was tested, no specific humoral response against NeuGc-containing gangliosides was detected in sera from immunized mice. However, hyperimmune sera from melanoma and breast cancer patients vaccinated with this Ab2 mAb were able to react specifically with these gangliosides. The different expression of NeuGc-containing gangliosides in the normal tissues of mice and humans could explain these results. In order to demonstrate these findings in other animal species with a different NeuGc-sialic acid expression, we performed similar studies in monkeys and chickens. In monkeys, as in most mammals, NeuGc-containing gangliosides are self-antigens. In contrast, chickens, like humans, lack the expression of these antigens in normal tissues. Here we report that the antibody response against NeuGc-containing gangliosides induced by immunization with 1E10 mAb was completely different in both species. No specific antibody response against these gangliosides was detected in hyperimmune monkey sera. In contrast, a strong and specific Ab3 response against GM3(NeuGc) and GM2(NeuGc) gangliosides (Ab3, Ag+) was generated in chickens due to the administration of 1E10 mAb.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16076030     DOI: 10.1016/j.imbio.2005.02.002

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  11 in total

Review 1.  Cancer vaccines and carbohydrate epitopes.

Authors:  Jamie Heimburg-Molinaro; Michelle Lum; Geraldine Vijay; Miten Jain; Adel Almogren; Kate Rittenhouse-Olson
Journal:  Vaccine       Date:  2011-10-01       Impact factor: 3.641

2.  Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.

Authors:  Alejandro López-Requena; Oscar R Burrone; Michela Cesco-Gaspere
Journal:  Front Oncol       Date:  2012-11-09       Impact factor: 6.244

3.  Physicochemical and biological characterization of 1E10 anti-idiotype vaccine.

Authors:  Yoan J Machado; Yamilet Rabasa; Raquel Montesinos; José Cremata; Vladimir Besada; Dasha Fuentes; Adolfo Castillo; Kathya R de la Luz; Ana M Vázquez; Martin Himly
Journal:  BMC Biotechnol       Date:  2011-11-22       Impact factor: 2.563

4.  B-CD8+ T Cell Interactions in the Anti-Idiotypic Response against a Self-Antibody.

Authors:  Darel Martínez; Amaury Pupo; Lianet Cabrera; Judith Raymond; Nichol E Holodick; Ana María Hernández
Journal:  J Immunol Res       Date:  2017-04-09       Impact factor: 4.818

5.  Tumor-Associated Disialylated Glycosphingolipid Antigen-Revealing Antibodies Found in Melanoma Patients' Immunoglobulin Repertoire Suggest a Two-Direction Regulation Mechanism Between Immune B Cells and the Tumor.

Authors:  Beatrix Kotlan; Szabolcs Horvath; Klara Eles; Vanda K Plotar; Gyorgy Naszados; Katalin Czirbesz; Miri Blank; Emil Farkas; Laszlo Toth; Jozsef Tovari; Andras Szekacs; Yehuda Shoenfeld; Maria Godeny; Miklos Kasler; Gabriella Liszkay
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

6.  Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data.

Authors:  Ana M Vázquez; Ana M Hernández; Amparo Macías; Enrique Montero; Daniel E Gómez; Daniel F Alonso; Mariano R Gabri; Roberto E Gómez
Journal:  Front Oncol       Date:  2012-10-23       Impact factor: 6.244

7.  Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotype antibody targeting NeuGcGM3.

Authors:  Marcelo D Guthmann; Cecilia Venier; Darien Toledo; Valeria I Segatori; Daniel F Alonso; Leonardo Fainboim; Ana M Vázquez; Hector Ostrowski
Journal:  Front Immunol       Date:  2013-01-17       Impact factor: 7.561

8.  Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements.

Authors:  Maha Z Ladjemi
Journal:  Front Oncol       Date:  2012-11-06       Impact factor: 6.244

9.  Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry.

Authors:  Ana M H Vázquez; Nely Rodrèguez-Zhurbenko; Ana M V López
Journal:  Front Oncol       Date:  2012-11-20       Impact factor: 6.244

10.  Semi-synthetic vNAR libraries screened against therapeutic antibodies primarily deliver anti-idiotypic binders.

Authors:  Doreen Könning; Laura Rhiel; Martin Empting; Julius Grzeschik; Carolin Sellmann; Christian Schröter; Stefan Zielonka; Stephan Dickgießer; Thomas Pirzer; Desislava Yanakieva; Stefan Becker; Harald Kolmar
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.